Navigation Links
Omega-3 Fatty Acid Falls Short in Alzheimer's Trials
Date:7/12/2009

No significant benefits seen with DHA, either in terms of prevention or treatment

SUNDAY, July 12 (HealthDay News) -- Two trials that looked at whether the omega-3 fatty acid DHA might treat or prevent Alzheimer's disease have produced mixed results.

The studies were done because of "a long history of epidemiological studies that related fish consumption to cognitive function," explained Bill Thies, chief medical and scientific officer of the Alzheimer's Association. Fish is rich in DHA, but the research scheduled to be presented Sunday at the association's annual meeting in Vienna, Austria, used DHA derived from algae.

An 18-month study of people with mild to moderate Alzheimer's disease "did not show treatment benefit in the study population as a whole, and does not support use of DHA for treatment of Alzheimer's disease," said study author Dr. Joseph Quinn, an associate professor of neurology at Oregon Health and Science University.

However, Quinn added that there was "an encouraging analysis of a subpopulation of the larger study," showing a slower rate of decline in mental function among those who did not have the e4 version of the APOE gene. That version is known to increase the risk of developing Alzheimer's disease. Between 70 percent and 80 percent of people have that gene version, Quinn estimated.

Still, "we're not prepared to conclude that e4-negative people should be on DHA," Quinn said. "We don't know a mechanism that would account for a benefit in e4-negative people and we don't know if our exploratory analysis would be confirmed in future trials."

His study, funded by the U.S. National Institute on Aging, included 402 people, average age 76, with a daily dietary intake of less than 200 milligrams a day. Some took 2,000-milligram DHA supplements while others took a placebo. All underwent standard tests of mental function over the 18-month trial. The slower rate of decline seen in e4-deficient participants did not reach statistical significance.

The second study was a six-month trial of 900 milligrams a day of DHA in 485 people, average age 70, who did not have Alzheimer's disease but had mild complaints about memory loss. Those taking the supplement made fewer errors on one memory test.

That trial was funded by the Martek Biosciences Corp., which markets the DHA used in both studies.

The results indicate that DHA supplements are appropriate for "people who have very mild memory complaints, which applies to a large percentage of the population at this age," said Karin Yurko-Mauro, associate director of clinical research at Martek Biosciences. "We're not talking about a disease stage here."

The company is "looking at the potential for more trials," but is still evaluating data from the completed study, Yurko-Mauro said.

"The results are certainly interesting," Thies said. "There was some improvement in memory. Then you can get into a debate about what the real-world benefit would be of that improvement in memory."

What is needed, Thies said, is a major trial for people with no Alzheimer's disease but some memory problems. "DHA is a great candidate for such a trial because it is a food supplement that is currently available," he said.

Meanwhile, Thies said, "it is too early" to make a recommendation about use of DHA supplements to prevent loss of mental function. "You would want to see more information in normal people before you make a recommendation," Thies said. "In high doses, DHA does have side effects, so you would want to see a benefit to justify the risk you are taking. We need more work for that."

More information

The latest information on Alzheimer's disease is available from the Alzheimer's Association.



SOURCES: Bill Thies, Ph.D., chief medical and scientific officer, Alzheimer's Association, Chicago; Joseph Quinn, M.D., associate professor, neurology, Oregon Health and Science University, Portland; Karin Yurko-Mauro, Ph.D., associate director, clinical research, Martek Biosciences Corp., Columbia, Md.; July 12, 2009, Alzheimer's Association annual meeting, Vienna, Austria


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Omega-3s Benefit Heart Attack Survivors, Healthy Adults, Mothers and Infants
2. Omega-3 Fatty Acid Deficiency takes 96,000 Lives Annually in the US
3. Omega-3 Fatty Acids Key to Fetal Development - Possible Mercury Contamination Concerns in Some Fish Oil Avoided With Plant-based DHA in PreNexa(R) Prenatal Vitamins
4. Nordic Omega-3 Fishies from Nordic Naturals Offers Quality EPA and DHA for Children with Kid Pleasin Taste
5. Omega-3 Fatty Acids Might Curb Depression in Heart Patients
6. Omega-3 EPA: Treatment for a Heart Condition
7. Omega-3 fatty acids may benefit cancer patients undergoing major operations
8. Omega-3 EPA/DHA May Decrease Risk of Developing Prostate Cancer
9. Omega-3s May Benefit Newborns, Menopausal Women and Obese Individuals
10. Omega-3s of No Added Benefit to Heart Attack Patients
11. Omega-3 Fatty Acids Guard Against Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Omega-3 Fatty Acid Falls Short in Alzheimer's Trials
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: